Ventyx Biosciences, Inc. VTYX
Mar 6, 2026, 9:30 AM EST
52-week range unavailable
- YTD
- +55.04%
- 1 year
- +858.90%
- Market cap
- 1.00B
- YTD return
- +55.04%
- 1-year return
- +858.90%
- Volume
- 5.40M
- Open
- 14.00
- Previous close
- 14.00
- Day's range
- 14.00 – 14.00
- Earnings date
- Mar 5, 2026
Key statistics
- Enterprise value
- 982.56M
- PEG ratio
- -0.41
- Price / sales
- 0.00
- Price / book
- 5.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -24.86%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy0
- Buy0
- Hold5
- Sell0
- Strong sell0
Next earnings
Mar 5, 2026
Expected Mar 5, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 5, 2026 | Dec 30, 2025 | -0.38627 | — | — | — |
| Nov 6, 2025 | Sep 30, 2025 | -0.45 | -0.32 | +0.13 | +28.89% |
| Aug 7, 2025 | Jun 30, 2025 | -0.45 | -0.38 | +0.07 | +15.56% |
| May 8, 2025 | Mar 31, 2025 | -0.48 | -0.39 | +0.09 | +18.75% |
| Feb 27, 2025 | Dec 31, 2024 | -0.54 | -0.41 | +0.13 | +24.07% |
| Nov 7, 2024 | Sep 30, 2024 | -0.48 | -0.50 | -0.02 | -4.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 8, 2026 | Oppenheimer | down | Outperform | Perform |
| Jan 8, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
| Jan 8, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Jan 8, 2026 | UBS | down | Buy | Neutral |
| Jan 8, 2026 | LifeSci Capital | down | Outperform | Market Perform |
| Jan 8, 2026 | Canaccord Genuity | down | Buy | Hold |
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc. is a biopharmaceutical company in the clinical development phase, specializing in the creation of small molecule therapeutics for inflammatory and autoimmune disorders. The company's primary investigational drug, VTX958, a tyrosine kinase type 2 (TYK2) inhibitor, is currently undergoing Phase I clinical trials. This compound aims to address a range of immune-mediated conditions, including psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. Among its pipeline assets is VTX002, an oral sphingosine 1 phosphate receptor 1 (S1P1) modulator, which has advanced to Phase II clinical studies for the treatment of ulcerative colitis. Additionally, VTX2735, a peripherally targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor, is in Phase I development, intended to combat systemic inflammatory diseases affecting cardiovascular, hepatic, renal, and rheumatologic systems. Furthermore, Ventyx is engaged in the development of CNS-penetrant NLRP3 inhibitors, with the objective of providing therapies for neurological ailments such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Founded in 2018, Ventyx Biosciences, Inc. is headquartered in Encinitas, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 81
- Website
- lilly.com
News
Eli Lilly Expands Into Sleep Medicine With Centessa Buyout 
Crude Oil Down 2%; ISM Services PMI Surges In December 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday 
US Stocks Edge Higher; UniFirst Shares Fall After Q1 Results 
Market-Moving News for January 7th 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Why Penguin Solutions Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Tuesday's After-Market Session - 12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on VTYX — it syncs with the Stock Master app.